|
Exact Sciences Corporation (EXAS) Évaluation DCF
US | Healthcare | Medical - Diagnostics & Research | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Exact Sciences Corporation (EXAS) Bundle
Conçu pour la précision, notre calculatrice DCF des sciences exactes (EXAS) vous permet d'évaluer l'évaluation de la Sciences exactes avec les données financières en temps réel et une flexibilité complète pour modifier tous les paramètres clés pour l'amélioration des projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,491.4 | 1,767.1 | 2,084.3 | 2,499.8 | 2,758.9 | 3,219.2 | 3,756.2 | 4,382.9 | 5,114.1 | 5,967.4 |
| Revenue Growth, % | 0 | 18.49 | 17.95 | 19.93 | 10.37 | 16.68 | 16.68 | 16.68 | 16.68 | 16.68 |
| EBITDA | -632.9 | -617.7 | -386.7 | 41.9 | -789.3 | -791.2 | -923.1 | -1,077.2 | -1,256.9 | -1,466.6 |
| EBITDA, % | -42.43 | -34.96 | -18.56 | 1.68 | -28.61 | -24.58 | -24.58 | -24.58 | -24.58 | -24.58 |
| Depreciation | 179.1 | 206.2 | 226.2 | 206.6 | 214.9 | 325.7 | 380.0 | 443.4 | 517.4 | 603.7 |
| Depreciation, % | 12.01 | 11.67 | 10.85 | 8.27 | 7.79 | 10.12 | 10.12 | 10.12 | 10.12 | 10.12 |
| EBIT | -811.9 | -823.9 | -612.9 | -164.7 | -1,004.2 | -1,116.8 | -1,303.1 | -1,520.5 | -1,774.2 | -2,070.2 |
| EBIT, % | -54.44 | -46.62 | -29.41 | -6.59 | -36.4 | -34.69 | -34.69 | -34.69 | -34.69 | -34.69 |
| Total Cash | 1,840.0 | 1,030.5 | 632.1 | 777.6 | 1,038.0 | 1,657.0 | 1,933.5 | 2,256.1 | 2,632.5 | 3,071.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 233.2 | 216.6 | 158.0 | 203.6 | 249.0 | 339.0 | 395.5 | 461.5 | 538.5 | 628.3 |
| Account Receivables, % | 15.64 | 12.26 | 7.58 | 8.15 | 9.02 | 10.53 | 10.53 | 10.53 | 10.53 | 10.53 |
| Inventories | 92.3 | 105.0 | 118.3 | 127.5 | 162.4 | 185.3 | 216.3 | 252.3 | 294.4 | 343.6 |
| Inventories, % | 6.19 | 5.94 | 5.67 | 5.1 | 5.89 | 5.76 | 5.76 | 5.76 | 5.76 | 5.76 |
| Accounts Payable | 35.7 | 67.8 | 74.9 | 78.8 | 89.6 | 104.5 | 121.9 | 142.2 | 166.0 | 193.7 |
| Accounts Payable, % | 2.39 | 3.84 | 3.59 | 3.15 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| Capital Expenditure | -64.4 | -135.8 | -214.5 | -124.2 | -136.0 | -207.2 | -241.8 | -282.1 | -329.2 | -384.1 |
| Capital Expenditure, % | -4.31 | -7.68 | -10.29 | -4.97 | -4.93 | -6.44 | -6.44 | -6.44 | -6.44 | -6.44 |
| Tax Rate, % | -0.71499 | -0.71499 | -0.71499 | -0.71499 | -0.71499 | -0.71499 | -0.71499 | -0.71499 | -0.71499 | -0.71499 |
| EBITAT | -803.8 | -582.5 | -604.2 | -166.7 | -1,011.4 | -1,045.9 | -1,220.4 | -1,424.0 | -1,661.6 | -1,938.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -978.8 | -476.1 | -540.0 | -135.2 | -1,002.0 | -1,025.5 | -1,152.3 | -1,344.5 | -1,568.8 | -1,830.6 |
| WACC, % | 8.47 | 8.2 | 8.47 | 8.48 | 8.48 | 8.42 | 8.42 | 8.42 | 8.42 | 8.42 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5,338.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,867 | |||||||||
| Terminal Value | -29,093 | |||||||||
| Present Terminal Value | -19,421 | |||||||||
| Enterprise Value | -24,760 | |||||||||
| Net Debt | 2,154 | |||||||||
| Equity Value | -26,914 | |||||||||
| Diluted Shares Outstanding, MM | 184 | |||||||||
| Equity Value Per Share | -146.12 |
What You Will Receive
- Genuine EXAS Data: Preloaded financial metrics – including revenue and EBIT – based on actual and forecasted figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Adjustments: Automatic recalculations to evaluate the effects of changes on Exact Sciences Corporation’s fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth projections.
- Efficient and Precise: Avoid constructing models from the ground up while ensuring accuracy and adaptability.
Key Features
- 🔍 Real-Life EXAS Financials: Pre-filled historical and projected data for Exact Sciences Corporation (EXAS).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Exact Sciences’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Exact Sciences’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Download the Template: Acquire and open the Excel file featuring Exact Sciences Corporation’s (EXAS) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth rates, WACC, and capital expenditures.
- 3. Instant Results: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation possibilities.
- 5. Present with Assurance: Share professional valuation findings to bolster your strategic decisions.
Why Choose Exact Sciences Corporation (EXAS)?
- Innovative Solutions: Cutting-edge technologies for accurate cancer detection and diagnostics.
- Proven Results: Backed by extensive clinical research and data demonstrating effectiveness.
- Patient-Centric Approach: Focused on improving patient outcomes and enhancing the healthcare experience.
- Comprehensive Support: Dedicated resources and support for healthcare providers and patients alike.
- Industry Recognition: A trusted leader in the field of molecular diagnostics and precision medicine.
Who Should Use Exact Sciences Corporation (EXAS) Products?
- Healthcare Investors: Make informed decisions with advanced diagnostic tools and technologies.
- Medical Researchers: Streamline data analysis with comprehensive research solutions tailored for innovation.
- Clinicians: Enhance patient care by utilizing precise and reliable testing methodologies.
- Health Policy Makers: Gain insights into the impact of diagnostics on public health initiatives.
- Students and Educators: Explore real-world applications of molecular diagnostics in academic settings.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Exact Sciences Corporation (EXAS) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Exact Sciences Corporation (EXAS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.